Becton, Dickinson and Company BDX SPX
Company Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Why Investors Should Care
Offers a dividend yield of 2.73%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Sep 2025 Revenue of $21.84B (+8.2% YoY); net profit $1.68B.
- Trailing 12 Months Year-on-year growth — revenue +5.2%, earnings -1.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.2%, profit CAGR 4.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.17% |
| 1 Year: | 5.20% |
Compounded Profit Growth
| 5 Years: | 4.04% |
| 1 Year: | -1.58% |
Stock Price Performance
| 1 Year: | +13.98% |
| 6 Months: | -1.52% |
| 3 Months: | +0.16% |
| 1 Month: | +5.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.11 · Neutral
P/E of 27.08 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.73%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BDX Becton, Dickinson and Company SPX | 154.88 | 27.08 | $42.68B | 2.73% | 5.49% | 6.67% | 7.17% | 4.04% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 2.92B | 2.97B | 3.04B | 3.17B | 3.08B | 4.22B | 4.28B | 4.40B | 4.16B | 4.20B | 4.35B | 4.58B | 4.22B | 4.25B | 3.85B | 4.78B | 5.32B | 4.91B | 4.61B | 4.72B | 4.75B | 4.64B | 4.59B | 4.82B | 4.88B | 4.71B | 5.04B | 4.99B | 5.17B | 4.48B | 5.51B | 5.25B | 4.71B |
| Gross Profit | 1.05B | 1.17B | 1.43B | 1.41B | 1.48B | 1.55B | 1.55B | 1.45B | 1.43B | 1.50B | 1.55B | 1.55B | 1.61B | 2.02B | 2.09B | 1.97B | 1.97B | 2.07B | 2.27B | 1.98B | 1.73B | 1.66B | 2.21B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 293.00M | 137.00M | - | 352.00M | 466.00M | 516.00M | - | 811.00M | 446.00M | -223.00M | - | 235.00M | 186.00M | 512.00M | - | 888.00M | 136.00M | 626.00M | - | 501.00M | 370.00M | 358.00M | - | 1.24B | 434.00M | 492.00M | 692.00M | 564.00M | 537.00M | 585.00M | 628.00M | 549.00M | 439.00M | 734.00M | 602.00M | 453.00M | 383.00M | 882.00M | 552.00M | 93.00M |
| Net Income | 216.00M | 62.00M | 181.00M | 229.00M | 338.00M | 390.00M | 19.00M | 562.00M | 344.00M | -132.00M | 327.00M | -136.00M | -12.00M | 594.00M | -135.00M | 599.00M | 20.00M | 451.00M | 163.00M | 278.00M | 183.00M | 286.00M | 128.00M | 1.00B | 299.00M | 525.00M | 677.00M | 454.00M | 360.00M | 509.00M | 460.00M | 407.00M | 281.00M | 537.00M | 487.00M | 303.00M | 308.00M | 574.00M | 382.00M | -311.00M |
| Diluted EPS | 1.08 | 0.29 | 0.84 | 1.06 | 1.56 | 1.80 | 0.09 | 2.58 | 1.58 | -0.75 | 1.24 | -0.76 | -0.19 | 2.03 | -0.64 | 2.05 | -0.07 | 1.51 | 0.45 | 0.87 | 0.53 | 0.97 | 0.36 | 3.35 | 0.94 | 1.72 | 2.28 | 1.50 | 1.18 | 1.70 | 1.53 | 1.36 | 0.96 | 1.85 | 1.68 | 1.04 | 1.07 | 2.00 | 1.34 | -1.11 |
| R&D Expense | 129.00M | 178.00M | - | 187.00M | 182.00M | 207.00M | - | 182.00M | 187.00M | 186.00M | - | 191.00M | 259.00M | 277.00M | - | 258.00M | 252.00M | 282.00M | - | 270.00M | 264.00M | 262.00M | - | 291.00M | 317.00M | 330.00M | 314.00M | 327.00M | 315.00M | 313.00M | 337.00M | 306.00M | 290.00M | 299.00M | 299.00M | 343.00M | 232.00M | 297.00M | 306.00M | 249.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.28B | 6.90B | 6.99B | 7.12B | 7.58B | 7.71B | 8.05B | 8.45B | 10.28B | 12.48B | 12.09B | 15.98B | 17.29B | 16.07B | 19.13B | 18.87B | 19.37B | 20.18B | 21.84B |
| Gross Profit | - | - | - | - | - | - | - | 4.30B | 4.70B | 5.99B | 5.94B | 7.27B | 8.29B | 7.58B | - | - | - | - | - |
| Operating Income | 1.18B | 1.49B | 1.59B | 1.58B | 1.67B | 1.56B | 1.25B | 1.61B | 1.07B | 1.43B | 1.52B | 1.51B | 1.76B | 912.00M | 2.25B | 2.28B | 2.11B | 2.40B | 2.58B |
| Net Income | 890.03M | 1.13B | 1.23B | - | - | 1.17B | 1.29B | 1.19B | 695.00M | 976.00M | 1.10B | 311.00M | 1.23B | 874.00M | 2.09B | 1.78B | 1.48B | 1.71B | 1.68B |
| Diluted EPS | 3.49 | 4.46 | 4.99 | 5.49 | 5.62 | 5.59 | 6.49 | 5.99 | 3.35 | 4.49 | 4.60 | 0.60 | 3.94 | 2.71 | 6.85 | 5.88 | 4.94 | 5.86 | 5.82 |
| R&D Expense | - | - | 404.57M | 422.77M | 470.00M | 472.00M | 494.00M | 550.00M | 632.00M | 828.00M | 770.00M | 1.00B | 1.06B | 1.04B | 1.28B | 1.26B | 1.24B | 1.19B | 1.26B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2006 | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.91B | 9.30B | 9.65B | 10.43B | 11.36B | 12.15B | 12.38B | 26.48B | 25.59B | 37.73B | 53.90B | 51.77B | 54.01B | 53.87B | 52.93B | 52.78B | 57.29B | 55.33B |
| Total Equity | - | - | 4.94B | 5.14B | 5.43B | 4.83B | 4.14B | 5.04B | 5.05B | 7.16B | 7.63B | 12.95B | 20.99B | 21.08B | 23.77B | 23.68B | 25.28B | 25.80B | 25.89B | 25.39B |
| Cash & Equivalents | 1.00B | 511.48M | 830.48M | 1.39B | 1.22B | 1.18B | 1.67B | 1.89B | 1.86B | 1.42B | 1.54B | 14.18B | 1.14B | 536.00M | 2.83B | 2.28B | 1.01B | 1.42B | 1.72B | 641.00M |
| Long Term Debt | - | - | - | 1.49B | 1.50B | 2.48B | 3.76B | 3.76B | 3.77B | 11.37B | 10.55B | 18.67B | 18.89B | 18.08B | 17.22B | 17.11B | 13.89B | 14.74B | 17.94B | 17.62B |
| Current Liabilities | - | - | 1.42B | 1.78B | 1.67B | 1.82B | 1.98B | 2.13B | 2.23B | 4.38B | 4.40B | 3.34B | 7.22B | 5.66B | 5.84B | 6.63B | 7.81B | 6.64B | 8.96B | 8.31B |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | 1.75B | 1.73B | 2.56B | 2.55B | 2.87B | 3.33B | 3.54B | 4.65B | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | -948.00M | -8.32B | -669.00M | -883.00M | -15.73B | -741.00M | -1.23B | -1.88B | - | -716.00M | -5.51B | -818.00M |
| Financing Cash Flow | - | - | - | - | - | - | - | -807.00M | 6.19B | -1.76B | 10.98B | -58.00M | -3.22B | 22.00M | -3.31B | - | -1.96B | 2.09B | -3.62B |
| Capital Expenditure | -556.29M | -595.81M | -585.20M | -530.97M | -509.00M | -487.00M | -522.00M | -592.00M | -596.00M | -693.00M | -727.00M | -895.00M | -957.00M | -769.00M | -1.19B | -973.00M | -874.00M | -725.00M | -760.00M |
| Free Cash Flow | - | - | - | - | - | - | - | 1.15B | 1.13B | 1.87B | 1.82B | 1.97B | 2.37B | 2.77B | 3.45B | - | - | - | - |
| Share Buybacks | 450.12M | 450.00M | 550.01M | 750.00M | 1.50B | 1.50B | 450.00M | 400.00M | 0 | 0 | 220.00M | 0 | 0 | 0 | 1.75B | 500.00M | 0 | 500.00M | 1.00B |
Ratios (Annual)
Figures in %.
| Metric | Sep 2007 | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 50.9% | 45.7% | 48.0% | 49.1% | 45.5% | 47.9% | 47.1% | - | - | - | - | - |
| Operating Margin % | 18.9% | 21.6% | 22.8% | 22.2% | 22.0% | 20.2% | 15.6% | 19.0% | 10.4% | 11.5% | 12.6% | 9.4% | 10.2% | 5.7% | 11.8% | 12.1% | 10.9% | 11.9% | 11.8% |
| Net Margin % | 14.2% | 16.3% | 17.6% | - | - | 15.2% | 16.1% | 14.0% | 6.8% | 7.8% | 9.1% | 1.9% | 7.1% | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% |
| ROE % | - | 22.8% | 23.9% | - | - | 28.3% | 25.6% | 23.5% | 9.7% | 12.8% | 8.5% | 1.5% | 5.8% | 3.7% | 8.8% | 7.0% | 5.8% | 6.6% | 6.6% |
| ROCE % | - | 22.9% | 21.1% | 19.8% | 19.4% | 16.6% | 12.5% | 15.8% | 4.9% | 6.7% | 4.4% | 3.2% | 3.8% | 1.9% | 4.8% | 5.1% | 4.6% | 5.0% | 5.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.49% | 26.15M | $3.94B |
| 2 | Vanguard Capital Management LLC | 6.71% | 18.49M | $2.79B |
| 3 | Vanguard Portfolio Management LLC | 5.56% | 15.32M | $2.31B |
| 4 | State Street Corporation | 5.02% | 13.82M | $2.08B |
| 5 | First Eagle Investment Management, LLC | 4.33% | 11.93M | $1.80B |
| 6 | Invesco Ltd. | 3.69% | 10.17M | $1.53B |
| 7 | T. Rowe Price Investment Management, Inc. | 3.52% | 9.69M | $1.46B |
| 8 | Massachusetts Financial Services Co. | 3.30% | 9.10M | $1.37B |
| 9 | Geode Capital Management, LLC | 2.58% | 7.11M | $1.07B |
| 10 | Wellington Management Group, LLP | 2.40% | 6.62M | $996.58M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDX
How Barron’s Roundtable Panelists’ 2026 Picks Have Performed So Far
The S&P 500 index posted a total return of 9.9% from Jan. 2 through June 30. Here’s how our panelists’ picks did in that period.
BD to Announce Financial Results for its Third Quarter of Fiscal 2026
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026 to discuss the Company's financial results f…
The Wide Chasm Priced Into Boston Scientific Stock
If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.
Becton Dickinson (BDX) Stock Trades At A Discount On Cash Flow And Earnings
Becton Dickinson stock has fallen 22.8% year to date, yet the valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may now be trading at a discount to what the underlying ca…
Becton Dickinson (BDX) Joins New Russell Indexes, Is The Stock Below Fair Value?
Becton Dickinson (BDX) is back on investors’ radar after a reshuffle in Russell indices, with the stock added to the Russell Midcap Index and Russell Midcap Value Benchmark and removed from two Russell Top 200 indices. See our latest analys…
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BDX — Frequently Asked Questions
What is the current share price of Becton, Dickinson and Company (BDX)?
As of 2026-07-15 16:51 PDT, Becton, Dickinson and Company (BDX) trades at $154.88 on NYSE. Its 52-week range is $132.30 to $182.92.
What is the market capitalisation of BDX?
Becton, Dickinson and Company (BDX) has a market capitalisation of $42.68B on NYSE.
What is the P/E ratio of BDX?
BDX trades at a trailing price-to-earnings (P/E) ratio of 27.08. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.72.
Does BDX pay a dividend?
Becton, Dickinson and Company (BDX) currently offers a dividend yield of 2.73%.
What is the return on equity (ROE) of BDX?
BDX has a return on equity (ROE) of 6.67%. Its return on capital employed (ROCE) is 5.49%.
Is BDX a good stock to buy?
This page provides a data-driven analysis of Becton, Dickinson and Company (BDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.